Net Cash Provided by (Used in) Financing Activities of Neurogene Inc. from 31 Dec 2016 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Neurogene Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Mar 2025.
  • Neurogene Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $4,000.
  • Neurogene Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $184,071,000, a 99% increase from 2023.
  • Neurogene Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $92,482,000, a 39% increase from 2022.
  • Neurogene Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $66,531,000, a 8989% increase from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Neurogene Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $4,000 +$6,528,000 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q1 2024 $6,524,000 -$6,631,000 -6197% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q1 2023 $107,000 -$26,000 -20% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q1 2022 $133,000 -$149,000 -53% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q1 2021 $282,000 -$3,108,000 -92% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $3,390,000 +$3,392,000 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q1 2019 $2,000 -$201,000 -101% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q1 2018 $199,000 +$203,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q1 2017 $4,000 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1

Neurogene Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $184,071,000 +$91,589,000 +99% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $92,482,000 +$25,951,000 +39% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $66,531,000 +$65,799,000 +8989% 01 Jan 2022 31 Dec 2022 10-K 18 Mar 2024 2023 FY
2021 $732,000 -$76,403,000 -99% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 $77,135,000 -$5,102,000 -6.2% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $82,237,000 +$81,667,000 +14328% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $570,000 +$147,000 +35% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $423,000 -$70,689,000 -99% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020 2019 FY
2016 $71,112,000 01 Jan 2016 31 Dec 2016 10-K 07 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.